BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments

10 Feb, 2021

BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments
Photo by NeONBRAND on Unsplash

– BigHat Biosciences has raised $19m in Series A funding.
– The round was led by Andreessen Horowitz and included participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors.
– BigHat Biosciences is a novel protein therapeutics company and developer of an AI-guided antibody design platform.
– BigHat has experienced rapid growth during its proof-of-concept stage, reaching significant corporate and scientific milestones in its first 15 months.
– BigHat’s wet lab is actively producing and characterizing antibodies at scale.
– BigHat’s cloud-based AI/ML platform improves designs each round by combining active learning with assay modeling of critical biophysical properties leading to the highest quality sequences.

Artificial Intelligence Biotechnology Medical North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: